Chasing the personalized medicine dream through biomarker validation in colorectal cancer.
Colorectal cancer (CRC) is a major health burden worldwide. The optimal approach to the diagnosis, management, and treatment of CRC involves multidisciplinary and integrated management practices. The field is rapidly changing because of recent advancements in delineating the molecular basis of tumorigenesis, introduction of targeted therapy, varied patient response to mainstay chemotherapeutics, biological drugs, and the effective combination regimes being used for treatment. Recent meta-analysis studies, which tend to establish few clinically useful predictor biomarkers, identify inconsistent results and limitations of the trials. Therefore, molecular pathological epidemiology discipline initiatives are promising. Here, we provide an overview of the potential of biomarker validation for personalized medicine by focusing largely on metastatic (m)CRC. We also highlight new candidate predictive and prognostic biomarkers.
Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center, Thane Belapur Road, Rabale, Navi Mumbai 400701, Maharashtra, India; School of Life and Environmental Sciences, Centre for Chemistry and Biotechnology, Deakin University, Locked Bag 20000, Geelong, VIC 3220, Australia.
Harshali
H
Patil
Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center, Thane Belapur Road, Rabale, Navi Mumbai 400701, Maharashtra, India.
Shailaja Gada
SG
Saxena
School of Life and Environmental Sciences, Centre for Chemistry and Biotechnology, Deakin University, Locked Bag 20000, Geelong, VIC 3220, Australia.
Colin J
CJ
Barrow
School of Medicine, Centre for Molecular and Medical Research, Faculty of Health, Deakin University, Waurn Ponds, Geelong, VIC 3216, Australia.
Jagat R
JR
Kanwar
Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center, Thane Belapur Road, Rabale, Navi Mumbai 400701, Maharashtra, India. Electronic address: arnab.kapat@ril.com.
Arnab
A
Kapat
School of Medicine, Centre for Molecular and Medical Research, Faculty of Health, Deakin University, Waurn Ponds, Geelong, VIC 3216, Australia. Electronic address: rupinder.kanwar@deakin.edu.au.
Rupinder K
RK
Kanwar
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D058990:Molecular Targeted Therapy; D057285:Precision Medicine / Q000379:methods*
D014408:Biomarkers, Tumor